Skip to content
Sign in
Health · Global

Bharat Biotech cuts MOSQIVAC price under UNICEF-Gavi agreement

Bharat Biotech announced a roughly 40% price reduction for its MOSQIVAC malaria vaccine under an agreement executed by UNICEF and financially backed by Gavi. The deal is projected to save about $50 million and help up to one million more children receive the full four-dose course.

AI-assisted synthesis · Based on 5 outlets' reporting · Article text read from 2 of 5 outletsHow it's made

View timeline · 9 entries
5 outletsLatest reporting 3 min read
Coverage: Center OnlyL 0 · C 4 · R 0 · 1 unrated
Updat3 graphic: India
Updat3 graphic · Map data: Natural Earth Natural Earth (public domain)

What happened

Key facts

  • Bharat Biotech announced a nearly 40% price reduction for its MOSQIVAC malaria vaccine on Friday, October 23.
  • The company said UNICEF executed the agreement and Gavi financially backed it.
  • Bharat Biotech said the lower price could help protect 1 million more children and generate USD 50 million in savings.
  • Bharat Biotech said one child dies from malaria every minute.

The brief

Bharat Biotech announced that it will cut the price of its MOSQIVAC malaria vaccine by approximately 40% under an agreement executed by UNICEF and financially backed by Gavi, the Vaccine Alliance. The company said the lower price is expected to help reach up to one million more children, while the deal is projected to generate about $50 million in savings.

Fortune India specifies that those savings are intended for child immunisation programmes between 2027 and 2029. It also describes the reach estimate as applying to children who receive the full four-dose course.

Siasat.com reports the company’s estimate of one million additional children and the expected savings, but does not give that programme-savings period or the four-dose detail. The vaccine is RTS,S/AS01, sold by Bharat Biotech under the MOSQIVAC brand. Bharat Biotech said the vaccine was developed by GSK and is now manufactured by the Indian company.

The reported agreement concerns the price of this vaccine; the sources do not describe a change to its formulation or dosing schedule. The arrangement brings together a manufacturer, a vaccine developer, a procurement agency and a financing partner. UNICEF executed the agreement, while Gavi provided financial backing.

Fortune India says the pact followed major investments by GSK and Bharat Biotech intended to support long-term equitable access to RTS,S/AS01. The coverage does not detail the size or terms of those investments.

The immediate policy mechanism described is a lower vaccine price, with Fortune India identifying child immunisation programmes as the destination for projected savings. The $50 million figure is an estimate, as are the projected reach of up to one million additional children and the stated savings period.

Those outcomes are presented as expected effects of the agreement, not as results already achieved. Siasat.com reports Bharat Biotech’s statement that the price change could help protect another one million children. The company also said malaria remains a severe child-health concern, claiming that one child dies from the disease every minute.

That mortality claim is the company’s stated rationale for urgency; the reports do not provide a separate assessment of it. Fortune India gives a global scale figure, reporting an estimate of 282 million malaria cases and 610,000 deaths in 2024, with up to 95% of cases and deaths occurring in Africa.

These figures offer context for the access initiative, while the deal’s stated reach and savings remain projections tied to the vaccine-price reduction.

Why it matters

  • Children who could receive the full four-dose malaria vaccine course are the intended beneficiaries; the agreement projects up to one million additional children reached.
  • Child immunisation programmes are the stated destination for about $50 million in projected savings between 2027 and 2029.
  • A roughly 40% price cut is the specific mechanism behind the projected savings and wider vaccine access.
  • GSK and Bharat Biotech have a documented role in developing, manufacturing and investing in access to RTS,S/AS01; UNICEF executed the agreement and Gavi financially backed it.

What to watch next

  • Whether UNICEF and Gavi implement the price agreement for MOSQIVAC through child immunisation programmes.
  • Whether the projected savings accrue to child immunisation programmes during the stated 2027–2029 period.
  • Whether the agreement reaches up to one million additional children with the full four-dose course.
  • Whether Bharat Biotech, GSK, UNICEF or Gavi provide further details on the agreement’s implementation or the investments cited by Fortune India.

How it's being covered

Coverage analysisShow details
5 source articles · 5 unique outlets
Outlet political mix: Center Only· 4 Center · 1 unrated
Where the outlets are based: Asia 60% · Unknown 40%
Outlet political mix
Center Only
Left
Center
Right
0 outlets
4 outlets
0 outlets
The marker shows coverage balance: each unique outlet counts once. 1 unrated outlet is not included.
Geography
Where the outlets covering this story are based.
5 unique outletsDominant coverage: Asia
Coverage imbalance
  • Coverage is currently concentrated among Center-rated outlets (4 of 4 rated sources); comparatively few Left or Right-rated outlets have published on the event.
How we measure coverage

How outlets' accounts compare

1 framing difference · 2 uncorroborated claims · 2 information gaps
The reports repeat the same account with different emphasis; its central claims are not independently confirmed in the reporting Updat3 read.Compared across 2 reports whose article text Updat3 read; 3 other outlets were checked by headline only.
Framing / emphasis differences
Sources emphasise different angles, actors or consequences of the same reporting.
  • Fortune India specifies that the projected savings are for child immunisation programmes during 2027–2029 and that the additional children would receive the full four-dose course; Siasat.com focuses on the company’s estimate of one million more children and the savings.
Updat3: These are differences of emphasis, not disputes about what is reported. They do not show that the reported claims are true.
One-sided or uncorroborated claims
Claims that come from one party or one source family and are not independently corroborated.
  • Bharat Biotech said the price reduction would help protect another one million children and generate about $50 million in savings.
  • Fortune India reports estimates of 282 million malaria cases and 610,000 deaths globally in 2024, with up to 95% of cases and deaths occurring in Africa.
Updat3: Not independently corroborated yet — treat as a claim, not an established fact.
Not established by the reporting
Information the available reporting does not contain or confirm. This is a gap, not a disagreement.
  • The sources do not provide the agreement’s detailed terms, the vaccine’s revised price per dose, or a country-by-country implementation plan.
  • The estimated savings, additional reach and intended programme effects are projections; the reports do not provide realised outcomes.
Updat3: Updat3 cannot conclude anything about this from the current sources.

Timeline

Developments from this story's sources, dated background we compiled and fact-checked, and our earlier coverage. Each row says which.
  1. The United Nations founded UNICEF to provide assistance to children.
    Background · compiled and fact-checked by Updat3
  2. The vaccine’s development began in 1987, when GlaxoSmithKline and the Walter Reed Army Institute of Research began collaborating on a malaria vaccine.
    Background · from our historical context
  3. Gavi was launched to expand access to immunisation in lower-income countries.
    Background · compiled and fact-checked by Updat3
  4. Researchers published results from the Phase III RTS,S/AS01 trial, reporting reduced malaria episodes among vaccinated children.
    Background · compiled and fact-checked by Updat3
  5. The European Medicines Agency issued a positive scientific opinion on the RTS,S/AS01 malaria vaccine.
    Background · compiled and fact-checked by Updat3
  6. In 2021, Gavi identified funding, supply and delivery planning as necessary to move beyond the limited pilot phase.
    Background · from our historical context
  7. The immediate policy backdrop was the World Health Organization’s October 6, 2021 recommendation that RTS,S/AS01 be used to prevent malaria in children in areas with moderate to high transmission.
    Background · from our historical context
  8. The World Health Organization recommended the R21/Matrix-M malaria vaccine for children at risk.
    Background · compiled and fact-checked by Updat3
  9. The World Health Organization prequalified the R21/Matrix-M malaria vaccine.
    Background · compiled and fact-checked by Updat3

How we got here

The immediate policy backdrop was the World Health Organization’s October 6, 2021 recommendation that RTS,S/AS01 be used to prevent malaria in children in areas with moderate to high transmission. Gavi, the Vaccine Alliance, was launched in 2000 to expand access to immunisation in lower-income countries, while UNICEF, founded in 1946, became a major global supplier of vaccines.

In 2021, Gavi identified funding, supply and delivery planning as necessary to move beyond the limited pilot phase. The vaccine’s development began in 1987, when GlaxoSmithKline and the Walter Reed Army Institute of Research began collaborating on a malaria vaccine.

Original sources

5 articles from 5 outlets

Every story links to the reporting it was built from. How we choose sources

Spotted a factual error, a broken link or a misleading summary? Tell us.